Expert Interview
A look at Exact Sciences' blood-based colorectal cancer screening test and the results presented at the ESMO Congress this year
Ticker(s): EXASInstitution: Fred Hutch Cancer Center
- Molecular biologist, Gastroenterologist, and Medical Director of the Gastrointestinal Cancer Prevention Program at Fred Hutch Cancer Center
- Cares for hundreds of patients with GI cancers and precancers and people with genetic conditions that increase their risk of developing GI cancers
- His research centers on blood and stool biomarkers used in tests to detect cancer early, and on identifying new ways to prevent, detect and treat colon cancer and other gastrointestinal, or GI, cancers.
What is your opinion on the current blood-based colorectal cancer screening tests, such as the Shield assay and the new data from Exact Sciences?
Could you provide an overview of the current colorectal cancer screening guidelines, including who they are meant for and what the gold standard is?
How do you think the newly developed blood-based tests compare in terms of convenience and compliance compared to stool-based tests like Cologuard and FIT?
Do you believe these blood-based tests will replace Cologuard or FIT testing, or will they primarily serve patients who would otherwise not be screened?
What is your high-level opinion on the data presented by Exact Sciences at ESMO, and how does it compare to the Guardant Shield test?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
